The use of pegylated interferon a-2a in a cohort of Greek patients with mycosis fungoides

IFN a with its cytotoxic and immunological effects on tumorous T cells has been introduced in the treatment of cutaneous T-cell lymphoma since the 1980s. The reported experience (average response rates 45 –80%, further improved with combination schemes) is mostly based on the use of the recombinant IFN a-2a or IFN a-2b. However, these interferon formulations are no longer commercially available in Europe and therefore, the pegylated analogue (pegylated IFN a-2a, Pegasys; Hoffmann-La Roche) has been currently used to treat CTCLs.
Source: European Journal of Cancer - Category: Cancer & Oncology Authors: Tags: POSTER PRESENTATIONS: TREATMENTS Source Type: research